This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...

Markers in the blood can predict how multiple sclerosis will develop and what drugs will be ­effective, a study found.

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...

Jeeping for Multiple Sclerosis brings awareness and resources to the Heights ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed ...